The immunosuppressant FK506 uncovers a positive regulatory cross-talk between the Hog1p and Gcn2p pathways.
about
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants.Anti-diabetic and anti-obesity agent sodium tungstate enhances GCN pathway activation through Glc7p inhibition.Dimerization is required for activation of eIF2 kinase Gcn2 in response to diverse environmental stress conditions.
P2860
The immunosuppressant FK506 uncovers a positive regulatory cross-talk between the Hog1p and Gcn2p pathways.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
The immunosuppressant FK506 un ...... the Hog1p and Gcn2p pathways.
@en
The immunosuppressant FK506 un ...... the Hog1p and Gcn2p pathways.
@nl
type
label
The immunosuppressant FK506 un ...... the Hog1p and Gcn2p pathways.
@en
The immunosuppressant FK506 un ...... the Hog1p and Gcn2p pathways.
@nl
prefLabel
The immunosuppressant FK506 un ...... the Hog1p and Gcn2p pathways.
@en
The immunosuppressant FK506 un ...... the Hog1p and Gcn2p pathways.
@nl
P2093
P2860
P50
P356
P1476
The immunosuppressant FK506 un ...... n the Hog1p and Gcn2p pathways
@en
P2093
Abigail Rodríguez-Afonso
Rosario Gil-Mascarell
Rosario Perona
P2860
P304
33887-33895
P356
10.1074/JBC.M305220200
P407
P577
2003-06-17T00:00:00Z